Immunotherapy for Pediatric Brain Tumors: Past and Present

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2019 Sep 11

PMID 31504801

Citations 25

Authors

Jessica B Foster

Peter J Madsen

Meenakshi Hegde

Nabil Ahmed

Kristina A Cole

John M Maris

Adam C Resnick

Phillip B Storm

Angela J Waanders

Affiliations

Soon will be listed here.

Abstract

The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

Citing Articles

IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

Seblani M, Zannikou M, Duffy J, Levine R, Thakur A, Puigdelloses-Vallcorba M Res Sq. 2024; .

PMID: 39711568 PMC: 11661357. DOI: 10.21203/rs.3.rs-5398280/v1.

Emerging and Biological Concepts in Pediatric High-Grade Gliomas.

Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V Cells. 2024; 13(17.

PMID: 39273062 PMC: 11394548. DOI: 10.3390/cells13171492.

Pediatric extra-axial glioblastoma with bone invasion leading to a subcutaneous mass: A case report.

Hammoud M, Hmamouche O, Lakhdar F, Benzagmout M, Chakour K, Chaoui M Surg Neurol Int. 2024; 15:25.

PMID: 38344102 PMC: 10858785. DOI: 10.25259/SNI_809_2023.

The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.

Cao L, Xie W, Ma W, Zhao H, Wang J, Liang Z Front Immunol. 2023; 14:1238684.

PMID: 38094301 PMC: 10716463. DOI: 10.3389/fimmu.2023.1238684.

Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors.

Galvin R, Jena S, Maeser D, Gruener R, Huang R Cancers (Basel). 2023; 15(22).

PMID: 38001715 PMC: 10670190. DOI: 10.3390/cancers15225455.

References

Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S . Therapeutic cancer vaccines. J Clin Invest. 2015; 125(9):3401-12. PMC: 4588240. DOI: 10.1172/JCI80009. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Hayes R, Koslow M, Hiesiger E, Hymes K, Hochster H, Moore E . Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995; 76(5):840-52. DOI: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. View

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

Singh N, Perazzelli J, Grupp S, Barrett D . Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016; 8(320):320ra3. DOI: 10.1126/scitranslmed.aad5222. View

de Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E . Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004; 100(5 Suppl Pediatrics):492-7. DOI: 10.3171/ped.2004.100.5.0492. View

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

Blumenthal D, Yalon M, Vainer G, Lossos A, Yust S, Tzach L . Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016; 129(3):453-460. DOI: 10.1007/s11060-016-2190-1. View

10.

Barba D, Saris S, Holder C, Rosenberg S, Oldfield E . Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989; 70(2):175-82. DOI: 10.3171/jns.1989.70.2.0175. View

11.

Viana-Pereira M, Lee A, Popov S, Bax D, Al-Sarraj S, Bridges L . Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLoS One. 2011; 6(5):e20588. PMC: 3102740. DOI: 10.1371/journal.pone.0020588. View

12.

Ajina R, Zamalin D, Weiner L . Functional genomics: paving the way for more successful cancer immunotherapy. Brief Funct Genomics. 2018; 18(2):86-98. PMC: 6430032. DOI: 10.1093/bfgp/ely017. View

13.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

14.

Ardon H, de Vleeschouwer S, Van Calenbergh F, Claes L, Kramm C, Rutkowski S . Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2009; 54(4):519-25. DOI: 10.1002/pbc.22319. View

15.

Pollack I, Jakacki R, Butterfield L, Hamilton R, Panigrahy A, Potter D . Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem.... J Clin Oncol. 2014; 32(19):2050-8. PMC: 4067943. DOI: 10.1200/JCO.2013.54.0526. View

16.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

17.

. First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov. 2017; 7(10):OF1. DOI: 10.1158/2159-8290.CD-NB2017-126. View

18.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S . Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016; 126(8):3036-52. PMC: 4966331. DOI: 10.1172/JCI83416. View

19.

Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y . Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013; 21(11):2087-101. PMC: 3831041. DOI: 10.1038/mt.2013.185. View

20.

Tejada S, Alonso M, Patino A, Fueyo J, Gomez-Manzano C, Diez-Valle R . Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery. 2017; 83(5):1050-1056. DOI: 10.1093/neuros/nyx507. View